Volume 88, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Yellow fever (YF) vaccine-associated serious adverse events and changing YF epidemiology have challenged healthcare providers to vaccinate only travelers whose risk of YF during travel is greater than their risk of adverse events. We describe the travel characteristics and YF vaccine use among US travelers visiting Global TravEpiNet clinics from January of 2009 to March of 2011. Of 16,660 travelers, 5,588 (34%) had itineraries to areas with risk of YF virus transmission. Of those travelers visiting one country with YF risk ( = 4,517), 71% were vaccinated at the visit, and 20% were presumed to be immune from prior vaccination. However, travelers visiting friends and relatives (odds ratio [OR] = 2.57, 95% confidence interval [95% CI] = 1.27–5.22) or going to Nigeria (OR = 3.01, 95% CI = 1.37–6.62) were significantly more likely to decline vaccination. To optimize YF vaccine use, clinicians should discuss an individual's risk–benefit assessment of vaccination and close knowledge gaps regarding vaccine use among at-risk populations.

[open-access] This is an Open Access article distributed under the terms of the American Society of Tropical Medicine and Hygiene's Re-use License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Monath TP, Gershman M, Staples JE, Barrett ADT, Plotkin SA, Orenstein W, Offit PA, , 2012. Yellow fever vaccine. , eds. Vaccines. Philadelphia, PA: WB Saunders, 870968. [Google Scholar]
  2. Staples JE, Gershman M, Fischer M, , 2010. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 59: 127. [Google Scholar]
  3. Gubler DJ, , 2002. The global emergence/resurgence of arboviral diseases as public health problems. Arch Med Res 33: 330342.[Crossref] [Google Scholar]
  4. WHO, 2008. Outbreak news. Yellow fever, Paraguay. Wkly Epidemiol Rec 83: 105. [Google Scholar]
  5. WHO, 2011. Outbreak news. Yellow fever, Uganda. Wkly Epidemiol Rec 86: 3738. [Google Scholar]
  6. WHO, 2012. Yellow fever in Cameroon. Communicable Disease Surveillance and Response (CSR). Available at: http://www.who.int/csr/don/2012_02_03/en/index.html. Accessed March 13, 2012. [Google Scholar]
  7. UNWTO, 2011. UNWTO Tourism Highlights, 2011 Edition. Available at: http://mkt.unwto.org/sites/all/files/docpdf/unwtohighlights11enlr_1.pdf. Accessed December 28, 2012. [Google Scholar]
  8. Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, Marano N, Slade BA, Barnett ED, Brunette GW, Horan K, Staples JE, Kozarsky PE, Hayes EB, , 2008. Adverse event reports following yellow fever vaccination. Vaccine 26: 60776082.[Crossref] [Google Scholar]
  9. Seligman SJ, , 2011. Yellow fever virus vaccine-associated deaths in young women. Emerg Infect Dis 17: 18911893.[Crossref] [Google Scholar]
  10. LaRocque RC, Rao SR, Lee J, Ansdell V, Yates JA, Schwartz BS, Knouse M, Cahill J, Hagmann S, Vinetz J, Connor BA, Goad J, Oladele A, Alvarez S, Stauffer W, Walker P, Kozarsky P, Franco-Paredes C, Dismukes R, Rosen J, Hynes NA, Jacquerioz F, McLellan S, Hale D, Sofarelli T, Schoenfeld D, Marano N, Brunette G, Jentes ES, Yanni E, Sotir MJ, Ryan ET, the Global TravEpiNet Consortium; , 2011. Demographics, travel destinations, and pre-travel health care among U.S. international travelers in Global TravEpiNet. Clin Infect Dis 54: 455462.[Crossref] [Google Scholar]
  11. Centers for Disease Control and Prevention, 2011. Health Information for International Travel, 2012. Atlanta, GA: US Department of Health and Human Services, Public Health Service. [Google Scholar]
  12. Jentes ES, Poumerol G, Gershman MD, Hill DR, Lemarchand J, Lewis RF, Staples JE, Tomori O, Wilder-Smith A, Monath TP, , 2011. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis 11: 622632.[Crossref] [Google Scholar]
  13. WHO, 2011. International Travel and Health. Geneva: World Health Organization. [Google Scholar]
  14. Gershman M, Schroeder B, Jentes ES, Marano N, Brunette GW, , 2009. Yellow fever vaccine requirements and recommendations, by country. , ed. CDC Health Information for International Travel 2010. Atlanta, GA: US Public Health Service. [Google Scholar]
  15. Anonymous, 2009. World Development Report 2009: Reshaping Economic Geography. Available at: http://siteresources.worldbank.org/INTRANETTRADE/Resources/Internal-Training/WDR_2009_Reshaping_Economic_Georgraphy.pdf. Accessed January 7, 2013. [Google Scholar]
  16. Morel JG, Bokossa MC, Neerchal NK, , 2003. Small sample correction for the variance of GEE estimators. Biom J 45: 395409.[Crossref] [Google Scholar]
  17. Toovey S, Jamieson A, Holloway M, , 2004. Travelers' knowledge, attitudes and practices on the prevention of infectious diseases: results from a study at Johannesburg International Airport. J Travel Med 11: 1622.[Crossref] [Google Scholar]
  18. Hagmann S, Benavides V, Neugebauer R, Purswani M, , 2009. Travel health care for immigrant children visiting friends and relatives abroad: retrospective analysis of a hospital-based travel health service in a US urban underserved area. J Travel Med 16: 407412.[Crossref] [Google Scholar]
  19. LaRocque R, Rao S, Tsibris A, Lawton T, Barry MA, Marano N, Brunette G, Yanni E, Ryan E, , 2010. Pre-travel health advice-seeking behavior among US international travelers departing from Boston Logan International Airport. J Travel Med 17: 387391.[Crossref] [Google Scholar]
  20. Angell S, Cetron M, , 2005. Health disparities among travelers visiting friends and relatives abroad. Ann Intern Med 142: 6772.[Crossref] [Google Scholar]
  21. Bacaner N, Stauffer B, Boulware D, Walker P, Keystone J, , 2004. Travel medicine considerations for North American immigrants visiting friends and relatives. JAMA 291: 28562864.[Crossref] [Google Scholar]
  22. Leder K, Chen LH, Wilson ME, , 2012. Aggregate travel vs. single trip assessment: arguments for cumulative risk analysis. Vaccine 30: 26002604.[Crossref] [Google Scholar]
  23. Anonymous, 2011. WHO: Yellow Fever Reported Cases. Available at: http://apps.who.int/immunization_monitoring/en/globalsummary/timeseries/tsincidenceyfe.htm. Accessed January 24, 2012. [Google Scholar]
  24. Monath TP, Cetron MS, , 2002. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis 34: 13691378.[Crossref] [Google Scholar]
  25. Monath TP, , 2012. Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines 11: 427448.[Crossref] [Google Scholar]
  26. WHO, 2008. Update on progress controlling yellow fever in Africa 2004–2008. Wkly Epidemiol Rec 83: 449460. [Google Scholar]
  27. Schilthuis H, Goossens I, Ligthelm R, de Vlas S, Varkevisser C, Richardus J, , 2007. Factors determining use of pre-travel preventive health services by West African immigrants in The Netherlands. Trop Med Int Health 12: 990998.[Crossref] [Google Scholar]
  28. Hamer D, Connor B, , 2004. Travel health knowledge, attitudes and practices among United States travelers. J Travel Med 11: 2326.[Crossref] [Google Scholar]
  29. FDA, 2012. Biologic Product Shortages. Available at: http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/Shortages/default.htm. Accessed March 28, 2012. [Google Scholar]

Data & Media loading...

  • Received : 31 Jul 2012
  • Accepted : 26 Jan 2013
  • Published online : 01 May 2013

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error